|
Day 1
Day One: Monday, January 30
10:00 am Summit Registration
OPENING
PLENARY KEYNOTE SESSION
Macro Challenges and Strategic Solutions in Drug Discovery & Development
|
|
11:00 am Summit Welcome and Opening Address
Perspectives on Attrition Across the R&D Continuum
Review of survey results about the principal causes of attrition
Potential approaches for addressing attrition causes through the different
stages of R&D
Chris Clement, Director, Head of Project Office, Millennium Pharmaceuticals
Jan Malek, PA Consulting
|
 |
11:30 am The Use of Portfolio Management, Therapeutic Area Strategy and Biomarkers to Reduce Attrition in Drug Development |
Define the problem what are the factors impacting productivity with special
reference on attrition in drug development and a root cause analysis
of attrition.
Propose solutions - review the levers for increasing R&D productivity in
general and attrition in particular.
Focus on three levers for solving R&D productivity and especially attrition:
w
Therapeutic Areas
w
Biomarkers
Portfolio Management
Model and quantify the possible impact of using these levers to increase R&D productivity/decrease attrition
Ismail Kola, Ph.D., Senior Vice President, Site Head for Basic Research, Rahway, Merck Research
Laboratories |
 |
12:15 pm Balancing the R&D Model to Address Challenges within our Industry Today |
Catherine Strader, Ph.D., Executive Vice President, Discovery Research, Schering Plough Research Institute
|
1:00 pm Opening Luncheon (Sponsorship Available)
 |
2:15 pm Improving R&D by Addressing Bottlenecks for NCEs and NBEs in the Drug Discovery Process |
Risk-balancing the pipeline
Exploiting the technology cycles
Diversified lead generation
Innovation by pathway repositioning
Mikael Dolsten, M.D., Ph.D., Head of Corporate Division Pharma Research, Boehringer
Ingelheim Pharmaceuticals, Inc. |
EXECUTIVE
ROUNDTABLE DISCUSSIONS
3:00 pm Executive Roundtables
Concurrent round tables to discuss some of the more broad yet, poignant questions facing the industry. Each roundtable will be limited to twelve (12) participants and a facilitator. Additional roundtables and facilitators will be added to accomodate demand for specific topics that attract more than 12 participants.
Roundtable 1: Strategic and Decision-Making Improvements for Phase 2 Survival
Facilitator: Shama Kajiji, Ph.D., MBA, Director, Worldwide Project Management, Head, Attrition Analysis Office, PGRD, Pfizer
Roundtable 2: What Should the Industry Look Like in 20 Years and How Do We Get There?
Facilitator: Rainer Fuchs, Ph.D., Co-Head of Discovery Research, Biogen Idec Inc.
Roundtable 3:
How Can Tomograms of Proteins Assist in Selecting the Right Projects for Clinical Development?
Facilitator: Anders Εberg, CSO, Sidec Technologies AB, Sweden
Roundtable 4: How Do We Effectively Implement New Stagegate Criteria and Better Prioritize Projects within Our Portfolios?
Facilitator: James Resch, Ph.D., Director, Strategic Planning, Global Discovery Affairs, AstraZeneca
Roundtable 5: The Challenges, Risks and Rewards of Developing Multi-Indication Treatment Platforms
Facilitator: Jan Malek, PA Consulting
Roundtable 6: What Are the Risks and Rewards of Resurrecting Failed Compounds?
Facilitator: Paul Thonnard, Market Analyst, Lilly Forecasting, Eli Lilly & Co.
4:00 pm Networking Refreshment Break
PLENARY SESSION - ROUNDTABLE FINDINGS
4:30 pm Executive Panel: Roundtable Synopsis and Findings
Each roundtable group will designate a leader to sit on a panel and present a short summary of their discussion. A moderator will then open a discussion amongst all attendees addressing the most critical questions facing the industry.
5:45 pm Networking Cocktail Reception hosted by PA Consulting
|
